Wegovy HD is the new higher-dose version of semaglutide, dosed at 7.2 mg once weekly, and it costs $399 a month as a self-pay cash price through NovoCare Pharmacy. The FDA approved it on March 19, 2026. In its main trial, patients lost about 20.7% of their body weight on average, with roughly one in three losing 25% or more. The key thing to understand: Wegovy HD isn’t a starting dose. It’s for people who’ve already been on the standard 2.4 mg dose for at least four weeks and need more weight reduction. If you’re new to semaglutide, you start lower and may step up to it later.<\/p>\n
Here’s how the higher dose works, what it costs across every payment route, and how to tell whether it’s a fit.<\/p>\n
Wegovy HD contains the same active ingredient as regular Wegovy: semaglutide. The difference is the dose. For years, 2.4 mg weekly was the ceiling for injectable semaglutide. Wegovy HD raises that ceiling to 7.2 mg, three times higher, for patients whose weight loss stalled before they reached their goal.<\/p>\n
The approval came through a new FDA pathway called the Commissioner’s National Priority Voucher program, which accelerated the review. Wegovy HD launched in the US in April 2026 as a single-dose pen, taken once a week like the standard version. It’s worth knowing that the 7.2 mg dose was already approved in the UK and EU before the US cleared it.<\/p>\n
The label is specific about sequencing. You qualify for Wegovy HD after you’ve tolerated the 2.4 mg dose for at least four weeks and your prescriber decides additional weight reduction is clinically warranted. It’s a step-up option, not a first prescription.<\/p>\n
Wegovy HD’s approval rested on the STEP UP trial, which enrolled about 1,400 adults with obesity and no diabetes over 72 weeks (Wharton et al., Lancet Diabetes & Endocrinology 2025). The headline figure, around 20.7% average weight loss, reflects results if everyone stayed on treatment. Measured across everyone regardless of whether they stuck with it, the average was closer to 18 to 19%. Either way, roughly one in three people on 7.2 mg lost at least a quarter of their body weight, compared with about 15% of those on the 2.4 mg dose.<\/p>\n
For context, that pushes semaglitude into weight-loss territory that used to require the strongest injectables or surgery. The 2.4 mg dose in the same trial produced about 15 to 16%, so the higher dose adds a meaningful increment for people who’d plateaued.<\/p>\n
The safety profile matched what’s already known about semaglutide. Gastrointestinal effects (nausea, diarrhea, vomiting, constipation) were the most common and showed up more often at the higher dose. Wegovy HD carries the same boxed warning for thyroid C-cell tumors and isn’t for anyone with a personal or family history of medullary thyroid cancer or MEN-2. As with any semaglutide product, you stop it two months before a planned pregnancy.<\/p>\n
The list price for Wegovy HD is $1,349.02 per package, the same sticker as the standard pen. Almost nobody should pay that. Here’s the real range.<\/p>\n